Clinical Trial Update: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Teclistamab is being studied in a Phase 2 trial for relapsed or refractory multiple myeloma. The study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hematological Malignancies | Phase 2 | Status: ACTIVE_NOT_RECRUITING